ReviewBiochimica et biophysica acta. Reviews on cancer2025
Olfactomedin 4 in cancer development and progression.
Review in Biochimica et biophysica acta. Reviews on cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- OLFM4 orchestrates the immunosuppressive microenvironment and drives gallbladder cancer progression.Journal of cancer research and clinical oncology · 2026Article
- Influence of the drone brood homogenate on the gut integrity and cellular immunity: A pilot study on pigs.Veterinarni medicina · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Olfactomedin 4 (OLFM4) is endogenously expressed in several normal human tissues and exerts its biological functions through its diverse binding partners on both the cell surface and intracellularly. OLFM4 is involved in multiple cellular functions, such as proliferation, apoptosis, and adhesion. OLFM4 is also a target gene in several important inflammation- and cancer-related pathways, and OLFM4 plays important roles in both infectious and inflammatory diseases and a variety of cancers. Studies of OLFM4 expression and function in cancer development and progression in numerous cancers indicate that OLFM4 exerts tumor-suppressing or tumor-promoting effects depending on the tissue and cellular context, and that OLFM4 is aberrantly expressed and functionally involved in multiple human cancers through different mechanisms. In cancers where OLFM4 is upregulated or plays a tumor-promoting role, therapies designed to inhibit OLFM4 expression may be clinically beneficial. OLFM4 could also have utility as a biomarker for early detection and diagnosis of precancerous states in several human cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.